<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vtio</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник трансплантологии и искусственных органов</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Transplantology and Artificial Organs</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-1191</issn><publisher><publisher-name>Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15825/1995-1191-2019-3-100-110</article-id><article-id custom-type="elpub" pub-id-type="custom">vtio-1069</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Регенеративная медицина и клеточные технологии</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Regenerative Medicine and Cell Technologies</subject></subj-group></article-categories><title-group><article-title>Сравнительный анализ регенераторной активности клеток костного мозга и общей РНК, выделенной из них, при хроническом фиброзирующем повреждении печени</article-title><trans-title-group xml:lang="en"><trans-title>Comparative analysis of regenerative activity of bone marrow cells and total RNA extracted from them in chronic fibrosing liver disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гоникова</surname><given-names>З. З.</given-names></name><name name-style="western" xml:lang="en"><surname>Gonikova</surname><given-names>Z. Z.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гоникова Залина Залимгериевна. Адрес: 123182, Москва, ул. Щукинская, д. 1. Тел. (966) 188-33-33.</p></bio><bio xml:lang="en"><p>Gonikova Zalina Zalimgerievna. Address: 1, Shchukinskaya str., Moscow, 123182. Теl. (966) 188-33-33.</p></bio><email xlink:type="simple">zalina3392@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Никольская</surname><given-names>А. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikolskaya</surname><given-names>A. O.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кирсанова</surname><given-names>Л. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kirsanova</surname><given-names>L. A.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шагидулин</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Shagidulin</surname><given-names>M. Yu.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Онищенко</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Onishchenko</surname><given-names>N. A.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Севастьянов</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Sevastyanov</surname><given-names>V. I.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>01</day><month>10</month><year>2019</year></pub-date><volume>21</volume><issue>3</issue><fpage>100</fpage><lpage>110</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гоникова З.З., Никольская А.О., Кирсанова Л.А., Шагидулин М.Ю., Онищенко Н.А., Севастьянов В.И., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Гоникова З.З., Никольская А.О., Кирсанова Л.А., Шагидулин М.Ю., Онищенко Н.А., Севастьянов В.И.</copyright-holder><copyright-holder xml:lang="en">Gonikova Z.Z., Nikolskaya A.O., Kirsanova L.A., Shagidulin M.Y., Onishchenko N.A., Sevastyanov V.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.transpl.ru/vtio/article/view/1069">https://journal.transpl.ru/vtio/article/view/1069</self-uri><abstract><p>Цель работы – провести сравнительную оценку эффективности восстановительных процессов в печени после моделировании хронического фиброзирующего повреждения печени (ХФПП) при использовании мононуклеарных клеток костного мозга (ККМ) и общей РНК (оРНК) из ККМ. Материалы и методы. В работе использовано 140 крыс породы Вистар. На 100 крысах моделировали ХФПП, из которых 25 погибло. Выжившие 75 крыс (ХФПП сформировался к 3-му месяцу) были разделены на 3 группы: группа 1 – контроль (введение физиологического раствора); группа 2 – однократное введение оРНК из ККМ в дозе 30 мкг/100 г веса; группа 3 – однократное введение ККМ в дозе (30–35) × 106 клеток. Динамику восстановительных процессов в печени оценивали по летальности животных, а также по динамике восстановления биохимических показателей (АлАТ, АсАТ, ЩФ и общий белок) и морфологической картины печени на 7-е сутки и через 3, 6 и 9 месяцев. Достоверность различия сравниваемых величин оценивали по критерию t Стьюдента при р &lt; 0,05. Результаты. Летальность животных с ХФПП в группе 1 составила 12%, в группах 2 и 3 – по 4%; В группе 1 АлАТ и АсАТ восстанавливались до значений нормы через 2 мес., ЩФ – через 3 мес., а общий белок оставался сниженным более 4 мес. В группах 2 и 3 все показатели печеночного гомеостаза возвращались к значениям до моделирования ХФПП быстрее, чем в группе 1 (через 2 мес.), но в группе 2 скорость восстановления была выше, чем в группе 3. Показано, что нормализация функциональных показателей печени во всех группах опережала восстановление ее гистологической структуры. Активизация процессов дефиброзирования печени в группе 2 наступала через 3 мес., а в группах 1 и 3 – через 6 мес. Восстановление гистологической структуры печени в группе 2 происходило через 6 мес., а в группах 1 и 3 – через 9 мес. Заключение. ККМ и оРНК из ККМ в биологически эффективных дозах способствуют активизации восстановительных процессов в печени при ХФПП, однако регуляторное воздействие от применения оРНК проявляется раньше и является более эффективным.</p></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim: to conduct a comparative assessment of the effectiveness of liver regeneration occurring after induction of chronic fibrosing liver disease (CFLD) using bone marrow mononuclear cells (BMMCs) and total RNA (tRNA) extracted from BMMCs.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The study involved 140 Wistar rats. CFLD was modeled in 100 rats, of which 25 died. The surviving 75 rats (CFLD formed by the third month) were divided into 3 groups: Group 1 – control (administered with physiological saline); Group 2 – a single injection of tRNA from BMMCs at a dose of 30 μg/100g body weight; Group 3 – a single injection of BMMCs at a dose of (30–35) × 106 cells. The dynamics of regenerative processes in the liver was evaluated based on the animal mortality, dynamics of restoration of biochemical markers (ALAT, ASAT, alkaline phosphatase and total protein) and morphological picture of the liver on the seventh day and after three, six and nine months. The significance of differences in the compared values was determined through Student’s t-test for &lt;0.05.</p></sec><sec><title>Results</title><p>Results. Mortality in Group 1 was 12%, in Groups 2 and 3 – 4%; In Group 1, ALAT and ASAT were restored to normal values after two months, alkaline phosphatase after 3 months, and total protein remained low for over 4 months. In Groups 2 and 3, all hepatic homeostasis markers returned to the values they were before CFLD modeling faster than in Group 1 (after two months). However, in Group 2, the regeneration rate was higher than in Group 3. It was revealed that normalization of functional liver parameters in all groups were ahead of restoration of the histological structure of the liver. Liver defibrotic processes in Group 2 were activated after 3 months, and in Groups 1 and 3 – after 6 months. The histological structure of the liver was restored in Group 2 after 6 months, and in Groups 1 and 3 after 9 months.</p></sec><sec><title>Conclusion</title><p>Conclusion. BMMCs and tRNA extracted from them in biologically effective doses trigger liver regeneration in CFLD. However, regulatory effect from the use of tRNA appears earlier and is more effective. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая печеночная недостаточность</kwd><kwd>цирроз печени</kwd><kwd>клетки костного мозга</kwd><kwd>общая РНК</kwd><kwd>регенерация печени</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic liver failure</kwd><kwd>cirrhosis</kwd><kwd>bone marrow mononuclear cells</kwd><kwd>total RNA</kwd><kwd>liver regeneration</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterology. 2014 Jun 21; 20 (23): 7312–7324.</mixed-citation><mixed-citation xml:lang="en">Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterology. 2014 Jun 21; 20 (23): 7312–7324.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Halliday N, Westbrook RH. Liver transplantation: need, indications, patient selection and pre-transplant care. Br J Hosp Med (Lond). 2017; 78 (5): 252–259.</mixed-citation><mixed-citation xml:lang="en">Halliday N, Westbrook RH. Liver transplantation: need, indications, patient selection and pre-transplant care. Br J Hosp Med (Lond). 2017; 78 (5): 252–259.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Olivo R, Guarrera JV, Pyrsopoulos NT. Liver Transplantation for Acute Liver Failure. Clin Liver Dis. 2018 May; 22 (2): 409–417.</mixed-citation><mixed-citation xml:lang="en">Olivo R, Guarrera JV, Pyrsopoulos NT. Liver Transplantation for Acute Liver Failure. Clin Liver Dis. 2018 May; 22 (2): 409–417.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Люндуп АВ. Применение мезенхимальных стволовых клеток костного мозга при хроническом фиброзирующем повреждении печени (экспериментальное исследование): Автореферат дис. … канд. мед. наук. М., 2011. 26 с. Lundup AV. Application of bone marrow mesenchymal stem cells at chronic fibrotic liver damage (experimental study). The author’s abstract of thesis (cand. med. sciences). M., 2011. 26 p.</mixed-citation><mixed-citation xml:lang="en">Люндуп АВ. Применение мезенхимальных стволовых клеток костного мозга при хроническом фиброзирующем повреждении печени (экспериментальное исследование): Автореферат дис. … канд. мед. наук. М., 2011. 26 с. Lundup AV. Application of bone marrow mesenchymal stem cells at chronic fibrotic liver damage (experimental study). The author’s abstract of thesis (cand. med. sciences). M., 2011. 26 p.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Pai M, Zacharoulis D, Milicevic MN et al. Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis. Am J Gastroenterol. 2008; 103: 1952–1958.</mixed-citation><mixed-citation xml:lang="en">Pai M, Zacharoulis D, Milicevic MN et al. Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis. Am J Gastroenterol. 2008; 103: 1952–1958.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kuo TK, Hung S et al. Stem cell therapy for liver disease: parameters governing the success for using bone marrow mesenchymal stem cells. Gastroenterology. 2008; 134: 2111–2121.</mixed-citation><mixed-citation xml:lang="en">Kuo TK, Hung S et al. Stem cell therapy for liver disease: parameters governing the success for using bone marrow mesenchymal stem cells. Gastroenterology. 2008; 134: 2111–2121.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Souza BS, Nogueira RC, de Oliveira SA et al. Current status of stem cell therapy for liver diseases. Cell Transplant. 2009; 18: 1261–1279.</mixed-citation><mixed-citation xml:lang="en">Souza BS, Nogueira RC, de Oliveira SA et al. Current status of stem cell therapy for liver diseases. Cell Transplant. 2009; 18: 1261–1279.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Amer ME, El-Sayed SZ, El-Kheir WA et al. Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocytelike cells. Eur J Gastroenterol Hepatol. 2011; 23: 936– 941.</mixed-citation><mixed-citation xml:lang="en">Amer ME, El-Sayed SZ, El-Kheir WA et al. Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocytelike cells. Eur J Gastroenterol Hepatol. 2011; 23: 936– 941.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Takami T, Terai S, Sakaida I. Stem cell therapy in chronic liver disease. Current Opinion in Gastroenterology. 2012; 28: 203–208.</mixed-citation><mixed-citation xml:lang="en">Takami T, Terai S, Sakaida I. Stem cell therapy in chronic liver disease. Current Opinion in Gastroenterology. 2012; 28: 203–208.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bonzo LV, Ferrero I, Cravanzola C et al. Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut. 2008; 57: 223–231.</mixed-citation><mixed-citation xml:lang="en">Bonzo LV, Ferrero I, Cravanzola C et al. Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut. 2008; 57: 223–231.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Higashiyama R, Moro T, Nakao S et al. Negligible contribution of bone marrow derived cells to collagen production during hepatic fibrogenesis in mice. Gastroenterology. 2009 Oct; 137 (4): 1459–1466.</mixed-citation><mixed-citation xml:lang="en">Higashiyama R, Moro T, Nakao S et al. Negligible contribution of bone marrow derived cells to collagen production during hepatic fibrogenesis in mice. Gastroenterology. 2009 Oct; 137 (4): 1459–1466.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Carvalho AB, Quintannilha LF, Dias et al. Bone marrow multipotent mesenchymal stem cells do not reduce fibrosis or improve function in a rat model of severe chronic liver injury. Stem Cells. 2008; 26: 1307–1314.</mixed-citation><mixed-citation xml:lang="en">Carvalho AB, Quintannilha LF, Dias et al. Bone marrow multipotent mesenchymal stem cells do not reduce fibrosis or improve function in a rat model of severe chronic liver injury. Stem Cells. 2008; 26: 1307–1314.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bihari C, Anand L, Rooge S, Kumar D et al. Bone marrow stem cells and their niche components are adversely affected in advanced cirrhosis of the liver. Hepatology. 2016 Oct; 64 (4): 1273–1288.</mixed-citation><mixed-citation xml:lang="en">Bihari C, Anand L, Rooge S, Kumar D et al. Bone marrow stem cells and their niche components are adversely affected in advanced cirrhosis of the liver. Hepatology. 2016 Oct; 64 (4): 1273–1288.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Sipeki N, Antal-Szalmas P, Lakatos PL, Papp M. Immune dysfunction in cirrhosis. World J Gastroenterol. 2014 Mar 14; 20 (10): 2564–2577.</mixed-citation><mixed-citation xml:lang="en">Sipeki N, Antal-Szalmas P, Lakatos PL, Papp M. Immune dysfunction in cirrhosis. World J Gastroenterol. 2014 Mar 14; 20 (10): 2564–2577.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Garg V, Garg H, Khan A, Trehanpati N, Kumar A, Sharma BC et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology. 2012; 142: 505–512.</mixed-citation><mixed-citation xml:lang="en">Garg V, Garg H, Khan A, Trehanpati N, Kumar A, Sharma BC et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology. 2012; 142: 505–512.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136 (2): 215–233.</mixed-citation><mixed-citation xml:lang="en">Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136 (2): 215–233.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Peterson SM, Thompson JA, Ufkin ML, Sthyanarayana P, Liaw L, Congdon CB. Common features of microRNA target prediction tools. Frontiers in Genetics. 2014; 5: 23.</mixed-citation><mixed-citation xml:lang="en">Peterson SM, Thompson JA, Ufkin ML, Sthyanarayana P, Liaw L, Congdon CB. Common features of microRNA target prediction tools. Frontiers in Genetics. 2014; 5: 23.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Yan IK, Wang X, Asmann YW, Haga H, Patel T. Circulating Extracellular RNA Markers of Liver Regeneration. PLoS One. 2016; 11 (7).</mixed-citation><mixed-citation xml:lang="en">Yan IK, Wang X, Asmann YW, Haga H, Patel T. Circulating Extracellular RNA Markers of Liver Regeneration. PLoS One. 2016; 11 (7).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Li J, Jin W, Qin Y, Zhao W, Chang C, Xu C. Expression Profile and Function Analysis of LncRNAs during Priming Phase of Rat Liver Regeneration. PLoS One. 2016 Jun 21; 11 (6).</mixed-citation><mixed-citation xml:lang="en">Li J, Jin W, Qin Y, Zhao W, Chang C, Xu C. Expression Profile and Function Analysis of LncRNAs during Priming Phase of Rat Liver Regeneration. PLoS One. 2016 Jun 21; 11 (6).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Li C, Chang L, Chen Z, Liu Z, Wang Y, Ye Q. The role of lncRNA MALAT1 in the regulation of hepatocyte proliferation during liver regeneration. Int J Mol Med. 2017 Feb; 39 (2): 347–356.</mixed-citation><mixed-citation xml:lang="en">Li C, Chang L, Chen Z, Liu Z, Wang Y, Ye Q. The role of lncRNA MALAT1 in the regulation of hepatocyte proliferation during liver regeneration. Int J Mol Med. 2017 Feb; 39 (2): 347–356.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Lauschke VM, Rezayee F, Nordling Å, Hendriks DF, Bell CC, Sison-Young R et al. Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation. Hepatology. 2016; 64 (5): 1743–1756.</mixed-citation><mixed-citation xml:lang="en">Lauschke VM, Rezayee F, Nordling Å, Hendriks DF, Bell CC, Sison-Young R et al. Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation. Hepatology. 2016; 64 (5): 1743–1756.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Qiao J, Yao H, Xia Y, Chu P et al. Long non-coding RNAs expression profiles in hepatocytes of mice after hematopoietic stem cell transplantation. IUBMB Life. 2016 Mar; 68 (3): 232–241.</mixed-citation><mixed-citation xml:lang="en">Qiao J, Yao H, Xia Y, Chu P et al. Long non-coding RNAs expression profiles in hepatocytes of mice after hematopoietic stem cell transplantation. IUBMB Life. 2016 Mar; 68 (3): 232–241.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Huang L, Damle SS, Booten S, Singh P, Sabripour M et al. Partial Hepatectomy Induced Long Noncoding RNA Inhibits Hepatocyte Proliferation during Liver Regeneration. PLoS One. 2015 Jul 24; 10 (7).</mixed-citation><mixed-citation xml:lang="en">Huang L, Damle SS, Booten S, Singh P, Sabripour M et al. Partial Hepatectomy Induced Long Noncoding RNA Inhibits Hepatocyte Proliferation during Liver Regeneration. PLoS One. 2015 Jul 24; 10 (7).</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Mottaghitalab F, Rastegari A, Farokhi M, Dinarvand R, Hosseinkhani H et al. Prospects of siRNA applications in regenerative medicine. International Journal of Pharmaceutics. 2017 May 30; 524 (1–2): 312–329.</mixed-citation><mixed-citation xml:lang="en">Mottaghitalab F, Rastegari A, Farokhi M, Dinarvand R, Hosseinkhani H et al. Prospects of siRNA applications in regenerative medicine. International Journal of Pharmaceutics. 2017 May 30; 524 (1–2): 312–329.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Ma H, Shi X, Yuan X, Ding Y. IL-1β siRNA adenovirus benefits liver regeneration by improving mesenchymal stem cells survival after acute liver failure. Annals of Hepatology. 2016; 15 (2): 260–270.</mixed-citation><mixed-citation xml:lang="en">Ma H, Shi X, Yuan X, Ding Y. IL-1β siRNA adenovirus benefits liver regeneration by improving mesenchymal stem cells survival after acute liver failure. Annals of Hepatology. 2016; 15 (2): 260–270.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Тишевская НВ, Геворкян НМ, Бабаева АГ, Захаров ЮМ и др. Влияние суммарной РНК лимфоидных клеток селезенки на эритропоэз при экспериментальной полицитемии. Российский физиол. журнал им. И.М. Сеченова. 2015; 101 (4): 451–461. Tishevskaya NV, Gevorkyan NM, Babaeva AG, Zakharov YuM. The influence of the total RNA of lymphoid cells of the spleen on erythropoiesis at experimental polycythemia. Rossiyskiy fiziol. zhurnal im. I.M. Sechenova. 2015; 101 (4): 451–461.</mixed-citation><mixed-citation xml:lang="en">Тишевская НВ, Геворкян НМ, Бабаева АГ, Захаров ЮМ и др. Влияние суммарной РНК лимфоидных клеток селезенки на эритропоэз при экспериментальной полицитемии. Российский физиол. журнал им. И.М. Сеченова. 2015; 101 (4): 451–461. Tishevskaya NV, Gevorkyan NM, Babaeva AG, Zakharov YuM. The influence of the total RNA of lymphoid cells of the spleen on erythropoiesis at experimental polycythemia. Rossiyskiy fiziol. zhurnal im. I.M. Sechenova. 2015; 101 (4): 451–461.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Бабаева АГ, Геворкян НМ, Тишевская НВ, Головкина ЛЛ и др. О гемопоэтических свойствах рибонуклеиновой кислоты лимфоцитов периферической крови больных истинной полицитемией и здоровых доноров. Онкогематология. 2015; 2 (10): 58–62. Babaeva AG, Gevorkyan NM, Tishevskaya NV, Golovkina LL et al. About hematopoietic properties of ribonucleic acid of peripheral blood lymphocytes of patients with true polycythemia and healthy donors. Oncogematologiya. 2015; 2 (10): 58–62.</mixed-citation><mixed-citation xml:lang="en">Бабаева АГ, Геворкян НМ, Тишевская НВ, Головкина ЛЛ и др. О гемопоэтических свойствах рибонуклеиновой кислоты лимфоцитов периферической крови больных истинной полицитемией и здоровых доноров. Онкогематология. 2015; 2 (10): 58–62. Babaeva AG, Gevorkyan NM, Tishevskaya NV, Golovkina LL et al. About hematopoietic properties of ribonucleic acid of peripheral blood lymphocytes of patients with true polycythemia and healthy donors. Oncogematologiya. 2015; 2 (10): 58–62.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Бабаева АГ, Тишевская НВ, Геворкян НМ. О морфогенетических свойствах РНК лимфоидных и стволовых клеток при восстановительных процессах. РАН. Научно-исследовательский институт морфологии человека. М., 2016. 272 с. Babaeva AG, Tishevskaya NV, Gevorkyan NM. About morphogenetic properties of RNA of lymphoid and stem cells at regenerative processes. RAN Research Institute of human morphology. M., 2016. 272 p.</mixed-citation><mixed-citation xml:lang="en">Бабаева АГ, Тишевская НВ, Геворкян НМ. О морфогенетических свойствах РНК лимфоидных и стволовых клеток при восстановительных процессах. РАН. Научно-исследовательский институт морфологии человека. М., 2016. 272 с. Babaeva AG, Tishevskaya NV, Gevorkyan NM. About morphogenetic properties of RNA of lymphoid and stem cells at regenerative processes. RAN Research Institute of human morphology. M., 2016. 272 p.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology. 1997; 26 (3): 1335–1339.</mixed-citation><mixed-citation xml:lang="en">Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology. 1997; 26 (3): 1335–1339.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Серов ВВ. Сравнительная морфологическая характеристика хронических вирусных гепатитов В и С. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 1999; 9 (1): 36–40. Serov VV. Comparative morphological characteristics of chronic viral hepatitis B and C. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 1999; 9 (1): 36–40.</mixed-citation><mixed-citation xml:lang="en">Серов ВВ. Сравнительная морфологическая характеристика хронических вирусных гепатитов В и С. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 1999; 9 (1): 36–40. Serov VV. Comparative morphological characteristics of chronic viral hepatitis B and C. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 1999; 9 (1): 36–40.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Desmet VJ, Gerber M, Hoofnagle Jay H et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994; 19: 1513–1520.</mixed-citation><mixed-citation xml:lang="en">Desmet VJ, Gerber M, Hoofnagle Jay H et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994; 19: 1513–1520.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Бурганова ГР, Aбдулхаков СР, Гумерова АА и др. Изменение активности воспаления и выраженности фиброза у больных алкогольным циррозом печени после трансплантации аутогенных гемопоэтических стволовых клеток. Гены и клетки. 2012; VII (3): 34– 36. Burganova GR, Abdulkhakov SR, Gumerova AA et al. Changes of inflammation activity and fibrosis severity in patients with alcoholic liver cirrhosis after transplantation of autogenous hematopoietic stem cells. Genes and Cells. 2012; VII (3): 34–36.</mixed-citation><mixed-citation xml:lang="en">Бурганова ГР, Aбдулхаков СР, Гумерова АА и др. Изменение активности воспаления и выраженности фиброза у больных алкогольным циррозом печени после трансплантации аутогенных гемопоэтических стволовых клеток. Гены и клетки. 2012; VII (3): 34– 36. Burganova GR, Abdulkhakov SR, Gumerova AA et al. Changes of inflammation activity and fibrosis severity in patients with alcoholic liver cirrhosis after transplantation of autogenous hematopoietic stem cells. Genes and Cells. 2012; VII (3): 34–36.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
